Schedule 13D ownership disclosure

KalVista Pharmaceuticals Inc

Security class unavailable · CUSIP: 483497103

Event date: 2022-01-26

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
734,350
Percent of class
3.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000897069-22-000045
Form type
SC 13D/A
Filer
Frazier Life Sciences Public Fund, L.P.
CIK
CIK 1863769
Filed
Jan 31, 2022
Reporting period
Jan 26, 2022
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub